The impact of Gender, Inactivity and Obesity on basal and postprandial muscle protein synthesis.

Recruiting

• Conditions: inactiviteit; loss of muscle mass; muscle atrophy; 10018057; 10017998

• Registration Number: NL-OMON41407
• Lead Sponsor: niversiteit Maastricht

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 11 June 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 62

Inclusion Criteria

Substudy A:
-Normal weight (BMI 19-25 kg/m2)
-Middle-aged (age 30-55 yrs);Substudy B:
-Males
-Young to middle-aged (18-35 yrs);Substudy C:
-Males
-Middle-aged (30-55 yrs)
-Extreme obesity (BMI >35 kg/m2)
-Scheduled for bariatric bypass surgery

Exclusion Criteria

Substudy A:
- Currently smoking cigarettes or tobacco
- Allergies to milk proteins (whey or casein)
- A history of neuromuscular problems
-Diagnosed impaired renal (kidney stones, nephritis, nephritic syndrome, end-stage renal disease) or liver function (acute or chronic hepatitis, alcoholic liver disease, liver cirrhosis).
- Use of medications known to affect digestion and/or absorption (antacids, H-2-receptor blockers, proton pump inhibitors, NSAID*s) 7 days prior to the experimental test-day.
- Use of anticoagulants, blood diseases, allergy for lidocain.
- Use of medications known to affect protein metabolism (i.e. corticosteroids, non-steroidal anti-inflammatories, or acne medications).
- Participation in regular exercise for >3 week or >150 min/week.
- Type 2 diabetes (according to OGTT).;Substudy B:
- Currently smoking cigarettes or tobacco
- Allergies to milk proteins (whey or casein)
- Arthritic conditions
- A history of neuromuscular problems
- Diagnosed impaired renal or liver function
- Diagnosed impaired renal (kidney stones, nephritis, nephritic syndrome, end-stage renal disease) or liver function (acute or chronic hepatitis, alcoholic liver disease, liver cirrhosis)
- Use of medications known to affect digestion and/or absorption (antacids, H-2-receptor blockers, proton pump inhibitors, NSAID*s) 7 days prior to the experimental test-day
- Use of anticoagulants, blood diseases, allergy for lidocain
- Use of medications known to affect protein metabolism (i.e. corticosteroids, non-steroidal anti-inflammatories, or acne medications).
-History with deep venous thrombosis or pulmonary embolie.
-Participation in regular exercise for >3 week or >150 min/week.
-Type 2 diabetes (HbA1c>6.5%).;Substudy C:
- Allergies to milk proteins (whey or casein)
- A history of neuromuscular problems
- Diagnosed impaired renal or liver function
- Use of anticoagulants, blood diseases, allergy for lidocain
- Use of medications known to affect protein metabolism (i.e. corticosteroids, non-steroidal anti-inflammatories, or acne medications).
- Participation in regular exercise for >3 week or >150 min/week.
- Diagnosed type 2 diabetes, and/or use of blood glucose lowering medication

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Primary endpoint for all studies: Basal and postprandial muscle protein<br /><br>synthesis rates, expressed as fractional synthetic rate (FSR). </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Secondary endpoints: Rate of protein digestion and absorption.</p><br>